Interim Phase II Telaprevir Data Point To Possible Shortened Hep C Treatment Course
Vertex hopes to base Phase III trial design on 12-week dosing with telaprevir plus standard of care followed by standard of care for 12 weeks.
Vertex hopes to base Phase III trial design on 12-week dosing with telaprevir plus standard of care followed by standard of care for 12 weeks.